CASTLE ROCK, Colo., Aug. 29 /PRNewswire-FirstCall/ -- AspenBio Pharma, Inc. , an emerging bio-pharmaceutical company dedicated to the development of novel drugs and diagnostics for animals and humans, reported today the company has been invited to present at the annual Roth Capital Partners New York Investor Conference to be held September 5 and 6, 2007. More than 1,200 institutional investors are expected to attend the conference, which will be held at the Westin New York at Times Square.
AspenBio's CEO Richard Donnelly is scheduled to present on Thursday, September 6, at 2:00 P.M. Eastern Time. A simultaneous Webcast will be available at: http://www.wsw.com/webcast/roth13/apnb.ob.
Mr. Donnelly will discuss progress of AspenBio key products, including a specialized assay that detects a marker in the blood associated with appendicitis. According to three studies conducted during the past 33 months, including an ongoing 400 patient study, the company's AppyScore(TM) blood test has been able to identify patients with appendicitis at a very high sensitivity level of 94% to 97%. This compares to significantly lower diagnostic success rates for expensive CT scans, which are generally considered the best diagnostic method currently available for appendicitis. With the AppyScore emergency room triage test and its sister product, AppyScreen(TM), designed for physician offices, AspenBio is targeting a significant need for more economical, accurate and faster assessment of the appendicitis condition.
Roth Capital Partners Stock Conferences are among the largest in the nation for micro and small-cap companies in the technology, healthcare, financial services and consumer products sectors. For more information on the conference, please visit the conference website at http://rothconference.com, or call the conference desk at (800) 678-9147. For media inquiries and press credentials only, call (949) 720-5700.
About Roth Capital Partners, LLC
Since 1984, Roth Capital Partners has been a leader and innovator in the small and micro cap markets. Roth provides the full spectrum of investment banking services, including raising capital, research coverage, creating liquidity, trading and market making, merger and acquisition advisory services, sales support, and investor conferences. Visit www.rothcp.com for more information.
About AspenBio Pharma, Inc.
AspenBio Pharma is an emerging bio-pharmaceutical company dedicated to the discovery, development, manufacture, and marketing of novel proprietary products, including those that enhance the reproductive efficiency of animals and that have large worldwide market potential. The company was originally formed to produce purified proteins for diagnostic applications and has become a leading supplier of human hormones to many of the nation's largest medical diagnostic companies and research institutions. The company has successfully leveraged this foundational science and technology expertise to rapidly develop an enviable late-stage pipeline of several novel reproduction hormone analogs for wide-ranging therapeutic use initially in bovine and equine species. AspenBio Pharma continues to make exciting progress in the development and testing of its two first-generation blood-based human diagnostic tests designed to rapidly help diagnose or rule out appendicitis in patients complaining of abdominal pain. For more information, please visit: www.aspenbiopharma.com.
Contact: Scott Liolios or Ron Both Liolios Group, Inc. (949) 574-3860 ron@liolios.com
AspenBio Pharma, Inc.CONTACT: Scott Liolios or Ron Both of Liolios Group, Inc.,+1-949-574-3860, ron@liolios.com
Web site: http://www.aspenbiopharma.com//
